Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide in Combination With Ambrisentan for IgA Nephropathy
NCT07030894Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of EPI-EE and ambrisentan in IgA nephropathy (IgAN), sponsored by The First Hospital of Jilin University. Primary endpoint: Urine Protein-to-Creatinine Ratio at 36 weeks. Started Sep 2025; status: recruiting.
02
Drugs
EPI-EEambrisentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07030894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030894.